Get local results

 Current general location:  
Enter your location to see results closest to you.
We do not share your location with anyone.

Dasvidaniya, Drug Czar: Trump to Axe White House Drug Policy Office

The Trump administration is planning to eliminate the Office of National Drug Control Policy by zeroing-out funding for the office, NPR and CBS News reported late Friday afternoon.

According to a draft document from the White House budget office, the administration plans to cut the office’s funding by 94%. That would all but eliminate the office, which was created in 1989 by President George H.W. Bush. The ONDCP director has traditionally been known as the White House Drug Czar.

CBS News White House correspondent Jacqueline Alemany tweeted this photo of the draft budget:


The office had a 2017 budget of $388 million. The administration’s 2018 request clocks in at $24 million, and would entirely eliminate funding for High Intensity Drug Trafficking Areas and Drug-Free Communities Support Program. The High Intensity Drug Trafficking Areas program currently receives $254 million in federal funding.

“The FY 2018 Budget supports an effort to streamline ONDCP’s organization and to shift focus from duplicative and burdensome administrative tasks,” reads the White House budget office’s justification for the cuts.

Earlier this week, Pennsylvania Rep. Tom Marino withdrew from consideration as the next director of the ONDCP, and many speculated that Marino did not pass the White House’s background check.

Today’s news puts Marino’s withdrawal in an entirely new light. The Pennsylvania Congressman may simply have balked at running an office with no actual office.

Did Trump Just Fire Drug Czar Nominee Tom Marino?
Leafly Staff's Bio Image
Leafly Staff

Leafly is the world’s largest cannabis information resource, empowering people in legal cannabis markets to learn about the right products for their lifestyle and wellness needs. Our team of cannabis professionals collectively share years of experience in all corners of the market, from growing and retail, to science and medicine, to data and technology.

View Leafly Staff's articles